First patient dosed with the drug candidate IPN01194 in a Phase 1/2 trial
On April 30th 2024, AGV Discovery announced that the first participant was dosed in the Phase 1/2 clinical trial for the evaluation of IPN01194 in patients with MAPKm advanced solid tumors.
Show moreā¦